目的 观察乳腺癌患者血清结缔组织生长因子(CTGF)及Six1水平的变化。方法 应用酶联免疫吸附试验(ELISA)方法检测原发性乳腺癌患者(乳腺癌组,60例)、乳腺良性疾病患者(乳腺良性疾病组,45例)和正常对照者(正常对照组,20例)血清CTGF、Six1。分析乳腺癌患者血清CTGF、Six1水平与乳腺癌临床病理参数的关系,及血清CTGF与Six1水平的关系。结果 乳腺癌组、乳腺良性疾病组、正常对照组血清CTGF水平分别为(9.73±3.11)、(5.62±2.14)、(2.35±0.32)ng/m L,Six1水平分别为(6.68±2.26)、(3.74±0.85)、(1.96±0.38)ng/m L,乳腺癌组与乳腺良性疾病组、正常对照组比较,乳腺良性疾病组与正常对照组比较,P均〈0.05。乳腺癌患者血清CTGF水平与肿瘤直径、TNM分期、组织学分级、淋巴结转移有关(P均〈0.05),与年龄无关(P〉0.05);血清Six1水平与TNM分期、组织学分级、淋巴结转移有关(P均〈0.05),与年龄、肿瘤直径无关(P均〉0.05)。乳腺癌患者血清CTGF与Six1水平呈正相关(r=0.433,P〈0.05)。结论 乳腺癌患者血清CTGF、Six1水平升高,共同参与乳腺癌的发生发展。
Objective To observe the changes in levels of serum connective tissue growth factor (CTGF) and Six1 in patients with breast cancer. Methods The levels of serum CTGF and Sixl was detected in primary breast cancer patients (breast cancer group, n = 60), breast benign disease patients (breast benign disease group, n = 45) and normal control subjects (normal control group, n = 20) by ELISA, and the relationships between the levels of CTGF and Sixl and clinicopathological parameters of breast cancer were compared as well as the relationships between serum CTGF and Sixl. Results The levels of serum GTGF in the breast cancer group, breast benign disease group and normal control group were (9.73 ± 3.11 ), (5.62± 2.14 ) and (2.35 ± 0.32) ng/mL, repectively. In addition, the levels of serum Sixl in the breast cancer group, breast benign disease group and normal control group were ( 6.68 ± 2.26), (3.74 ± 0.85 ) and ( 1.96 ± 0.38 ) ng/mL, respectively. Significant difference was found between every two groups ( all P 〈 0.05 ). The level of serum CTGF in the breast cancer patients was related with diameter of tumor, TNM staging, histological grade and lymph node metastasis ( all P 〈O.O5 ) but was not related with age ( P 〉 0. 05 ). The level of serum Sixl was related with TNM staging, histological grade and lymph node metastasis (all P 〈 0.05 ) hut was not related with diameter of tumor or age (all P 〉 0.05 ). Serum CTGF and Six1 in breast cancer patients were positively correlated ( r = 0.433, P 〈 0.05 ). Conclusion The levels of serum CTGF and Sixl in breast cancer are increased, and both participate in the occurrence and development of breast cancer.